92 Safety and efficacy of recombinant interferon-gamma-1b (rIFN-γ1b) immune adjuvant in 20 patients receiving high-dose donor granulocyte transfusions (GTX): An observational study during 2000–2004  by Safdar, A. et al.
International Journal of Infectious Diseases (2006) 10($1) 52-72 
ELSEVIER http://int[.e[sevierhea[th.com/journa[s/ijid 
Abstracts 
Infections in Cancer and Hematological Malignancies 
92 
Safety and Efficacy of Recombinant 
Interferon-gamma-lb (rlFN-ylb)Immune 
Adjuvant in 20 Patients Receiving High-Dose 
Donor Granulocyte Transfusions (GTX): An 
Observational Study During 2000-2004 
A. Safdar*, G. Rodriguez, B. Lichtiger, R. Champ[in, 
E.J. Freireich, H.M. Kantarjian. 44.D. Anderson 
Cancer Center, Houston, TX, USA 
Background: Response to antimicrobia[ therapy 
alone is often sub-optimal in severely immuno- 
suppressed cancer patients with difficult-to-treat 
opportunistic infections (OIs). 
Methods: Patients receiving G-CSF donor primed 
(-5.5 × 10 l° per transfusion) GTX plus rIFN-y1 b were 
evaluated. 
Results: The mean age was 43±17y, 10 (50%) were 
men, 16 (80%) had acute leukemia, 3 (15%) MDS 
and APACHE -II score was 19+17 (range, 17-22). 
Most patients (n = 18, 90%) had relapse or refractory 
cancer. In 6 (30%) a[[ogeneic hematopoietic stem 
ceil transplantation (HSCT) recipients, GTX plus 
rlFN-ylb was given 594-100 (range, 12-372) days 
after transplantation. Seventeen patients (85%) 
had severe neutropenia during GTX plus cytokine 
therapy. In 19 patients (95%) with invasive fun- 
ga[ infection (IFI), 5 (25%) had possible, 3 (15%) 
probable and 8 of 11 (55%) with definitive IFI had 
disseminated systemic mycosis. One patient (5%) 
had refractory Pseudomonas sepsis. Eight patients 
(40%) were receiving >600 mg prednisone equiva- 
lent dose during GTX-cytokine therapy. Cytokine 
doses that accompanied 104-7 (range, 4-28) GTX 
included, 94-7 doses of rlFN-ylb (mean cumula- 
tive dose [c.d.] 11884-2621pg). Other concomi- 
tant cytokines were G-CSF 124-3 G-CSF doses 
(c.d. 71284-4721 pg) in 15 patients (75%) and GM- 
CSF 124-9 doses (c.d. 56244-4410pg) in 14 pa- 
tients (70%). In 2 patients with fever and one 
patient each with skin rash and transient dyspnea 
were attributed to GTX. In 8 patients, 3 each 
with fever, and reversible liver dysfunction, and 
1 each with fever, and tachycardia were considered 
rlFN-ylb associated adverse reactions. Four weeks 
after therapy, 9 patients (45%) had completed or 
partial response; another 3 (15%) had stable sys- 
temic mycosis. 
Conclusions: Adjuvant GXT plus rlFN-ylb ther- 
apy was tolerated without serious adverse reac- 
tions. Therapeutic efficacy needs further prospec- 
tive evaluation. 
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A Trial of Increasing Dose of Baculovirus- 
Expressed Trivalent Influenza HA Vaccine: 
Prospective, Randomized, Double-Blind Study 
in Adult Patients with B-Cell Non-Hodgkin's 
Lymphoma (NHL) 
A. Safdar*, A. Rodriguez, F.E. Luis, J.E. Romaguera, 
EB. Hagemeister, RW. McLaugh[in, L. Kwak, 
R.B. Couch. M.D. Anderson Cancer Center 
(MDACC), and Baylor College of Medicine (BCM), 
Houston, TX, USA 
Background: Response of conventional influenza 
vaccine is impaired in patients with hematologic 
cancer. We hypothesized that an increased close 
of the hemagg[utinin (HA) antigen may improve 
protective immune response in patients with NHL. 
A recombinant HA antigen (rHAO) was used for this 
test. 
Methods: Twenty-seven patients were random- 
ized to receive one of the four vaccines be- 
tween August 23 and October 23, 2004. The 
SV was commercially avai[ab[e triva[ent vac- 
cine from a single lot containing 15pg per 
0.5m[ each of the hemagg[utinin (HA) of in- 
fluenza A/Panama/2007/99 (H3N2), A/New Cale- 
donia/20/99 (H1N1) and B/Hong Kong/330/2001 
(Aventis Pasteur, USA). The rHA0 consisted of HA 
proteins expressed in insect (SF9) ceils by recom- 
binant bacu[ovirus. The HA genes used were the 
same as those in the SV vaccine. The rHA0 vaccine 
was given in three final concentrations as deter- 
mined in assays for total protein; these were 15 pg, 
45pg, and 135pg of HA per 0.5m[ dose. The pre-, 
4- and 8-week post-vaccination antibody titers 
were measured from coded specimens. Test viruses 
for hemagg[utination-inhibition antibody (HIA) as- 
says were the same as the vaccine viruses; the 
